The trajectory of companies tied to Sildenafil's past presents a intricate investment picture . While the initial surge generated substantial gains, generic copies have significantly diminished sales . Investing in associated pharmaceutical companies now requires a discerning assessment of patent rights , evolving medical changes, and the potential